Lapachone
Star0
This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Lapachone
- DrugBank Accession Number
- DB11948
- Background
Lapachone has been used in trials studying the treatment of Cancer, Carcinoma, Advanced Solid Tumors, Head and Neck Neoplasms, and Carcinoma, Squamous Cell.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 242.274
Monoisotopic: 242.094294311 - Chemical Formula
- C15H14O3
- Synonyms
- Not Available
- External IDs
- ARQ 501
- ARQ-501
- MB-12066
- NSC-26326
- NSC-629749
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism URetinol-binding protein 3 Not Available Humans - Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAdenovirus type 7 vaccine live The therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Lapachone. Anthrax vaccine The therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Lapachone. Bacillus calmette-guerin substrain connaught live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Lapachone. Bacillus calmette-guerin substrain russian BCG-I live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Lapachone. Bacillus calmette-guerin substrain tice live antigen The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Lapachone. BCG vaccine The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Lapachone. Human adenovirus e serotype 4 strain cl-68578 antigen The therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Lapachone. Rubella virus vaccine The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Lapachone. Typhoid Vaccine Live The therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Lapachone. Varicella zoster vaccine (live/attenuated) The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Lapachone. Identify potential medication risksEasily compare up to 40 drugs with our drug interaction checker.Get severity rating, description, and management advice.Learn more - Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as naphthopyranones. These are compounds containing a naphthopyran skeleton where a ring carbon bears a carboxylic acid group. Naphthtopyran is made up of the pyran ring fused to a naphthalene ring system.
- Kingdom
- Organic compounds
- Super Class
- Organoheterocyclic compounds
- Class
- Naphthopyrans
- Sub Class
- Naphthopyranones
- Direct Parent
- Naphthopyranones
- Alternative Parents
- Naphthoquinones / Quinones / Aryl ketones / Pyrans / Vinylogous esters / Oxacyclic compounds / Organic oxides / Hydrocarbon derivatives
- Substituents
- Aromatic heteropolycyclic compound / Aryl ketone / Benzenoid / Carbonyl group / Hydrocarbon derivative / Ketone / Naphthalene / Naphthopyranone / Naphthoquinone / Organic oxide
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- quinone, benzochromenone (CHEBI:10429)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 6N4FA2QQ6A
- CAS number
- 4707-32-8
- InChI Key
- QZPQTZZNNJUOLS-UHFFFAOYSA-N
- InChI
- InChI=1S/C15H14O3/c1-15(2)8-7-11-13(17)12(16)9-5-3-4-6-10(9)14(11)18-15/h3-6H,7-8H2,1-2H3
- IUPAC Name
- 2,2-dimethyl-2H,3H,4H,5H,6H-naphtho[1,2-b]pyran-5,6-dione
- SMILES
- CC1(C)CCC2=C(O1)C1=CC=CC=C1C(=O)C2=O
References
- General References
- Not Available
- External Links
- KEGG Compound
- C10367
- PubChem Compound
- 3885
- PubChem Substance
- 347828274
- ChemSpider
- 3748
- BindingDB
- 81348
- ChEBI
- 10429
- ChEMBL
- CHEMBL15192
- ZINC
- ZINC000001531790
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 2 Completed Not Available Cancer 1 2 Completed Treatment Adenocarcinomas / Pancreatic Cancer 1 2 Completed Treatment Head and Neck Neoplasms / Squamous Cell Carcinoma (SCC) 1 2 Terminated Treatment Fatty Liver, Non-alcoholic Fatty Liver Disease, NAFLD 1 1 Completed Screening Obesity / Syndrome, Metabolic 2 1 Completed Screening Syndrome, Metabolic 1 1 Completed Treatment Advanced Solid Tumors 1 1 Completed Treatment Cancer 1 1 Completed Treatment Carcinoma 1 1, 2 Completed Treatment Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.0563 mg/mL ALOGPS logP 2.82 ALOGPS logP 2.63 Chemaxon logS -3.6 ALOGPS pKa (Strongest Basic) -4.9 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 43.37 Å2 Chemaxon Rotatable Bond Count 0 Chemaxon Refractivity 69.09 m3·mol-1 Chemaxon Polarizability 25.65 Å3 Chemaxon Number of Rings 3 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter Yes Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
1. DetailsRetinol-binding protein 3
- Kind
- Protein
- Organism
- Humans
- Pharmacological action
- Unknown
- General Function
- Serine-type peptidase activity
- Specific Function
- IRBP shuttles 11-cis and all trans retinoids between the retinol isomerase in the pigment epithelium and the visual pigments in the photoreceptor cells of the retina.
- Gene Name
- RBP3
- Uniprot ID
- P10745
- Uniprot Name
- Retinol-binding protein 3
- Molecular Weight
- 135361.46 Da
Drug created at October 20, 2016 21:03 / Updated at June 12, 2020 16:53